Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.
Status:
Completed
Trial end date:
2020-06-03
Target enrollment:
Participant gender:
Summary
E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in
ulcerative colitis. However, data on ability of E.coli Nissle 1917 (Mutaflor®) to induce
remission compared with placebo is limited. Investigators aim to investigate the efficacy of
E.coli Nissle 1917 (Mutaflor®) as an add-on treatment to 5-ASA in mild to moderate ulcerative
colitis.